{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T20:18:53Z","timestamp":1790713133231,"version":"4.1.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,1,14]],"date-time":"2019-01-14T00:00:00Z","timestamp":1547424000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001826","name":"ZonMw","doi-asserted-by":"publisher","award":["843001805"],"award-info":[{"award-number":["843001805"]}],"id":[{"id":"10.13039\/501100001826","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s12885-019-5275-3","type":"journal-article","created":{"date-parts":[[2019,1,14]],"date-time":"2019-01-14T11:59:27Z","timestamp":1547467167000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Evaluation of effectiveness of the PlasmaJet surgical device in the treatment of advanced stage ovarian cancer (PlaComOv-study): study protocol of a randomized controlled trial in the Netherlands"],"prefix":"10.1186","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7074-6201","authenticated-orcid":false,"given":"G. M.","family":"Nieuwenhuyzen-de Boer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W.","family":"Hofhuis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Reesink-Peters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P. C.","family":"Ewing-Graham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I. G.","family":"Schoots","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. J.","family":"Beltman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. M. J.","family":"Piek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Baalbergen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G. S.","family":"Kooi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"van Haaften","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"van Huisseling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Haans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Dorman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H. J.","family":"van Beekhuizen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,1,14]]},"reference":[{"key":"5275_CR1","unstructured":"Oncoline richtlijn Epitheliaal Ovariumcarcinoom. https:\/\/www.oncoline.nl\/ovariumcarcinoom"},{"key":"5275_CR2","unstructured":"Netherlands Comprehensive Cancer Organisation IKNL. Data on Ovarian Cancer registration (not published)."},{"key":"5275_CR3","unstructured":"Beter Keten, regionaal jaarverslag 2014 ovariumcarcinoom2015: Available from: https:\/\/www.beterketen.nl\/bestanden\/regionaal_jaarverslag_2014_nieuw_ovariumcarcinoom.pdf ."},{"issue":"13","key":"5275_CR4","doi-asserted-by":"publisher","first-page":"4059","DOI":"10.1245\/s10434-012-2446-8","volume":"19","author":"SJ Chang","year":"2012","unstructured":"Chang SJ, Bristow RE, Ryu HS. Impact of complete cytoreduction leaving no gross residual disease associated with radical cytoreductive surgical procedures on survival in advanced ovarian cancer. Ann Surg Oncol. 2012;19(13):4059\u201367.","journal-title":"Ann Surg Oncol"},{"issue":"8","key":"5275_CR5","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.1097\/IGC.0b013e31826a3559","volume":"22","author":"M Luyckx","year":"2012","unstructured":"Luyckx M, Leblanc E, Filleron T, et al. Maximal cytoreduction in patients with FIGO stage IIIC to stage IV ovarian cancer: a retrospective French multicentric study. Int J Gynecol Cancer. 2012;22(8):1337\u201343.","journal-title":"Int J Gynecol Cancer"},{"key":"5275_CR6","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1186\/s12885-015-1525-1","volume":"15","author":"Y Ren","year":"2015","unstructured":"Ren Y, Jiang R, Yin S, et al. Radical surgery versus standard surgery for primary cytoreduction of bulky stage IIIC and IV ovarian cancer. BMC Cancer. 2015;15:583.","journal-title":"BMC Cancer"},{"key":"5275_CR7","doi-asserted-by":"publisher","first-page":"464123","DOI":"10.1155\/2015\/464123","volume":"2015","author":"MJ Rutten","year":"2015","unstructured":"Rutten MJ, Sonke GS, Westermann AM, et al. Prognostic value of residual disease after interval Cytoreductive surgery for epithelial ovarian Cancer. Obstet Gynecol Int. 2015;2015:464123.","journal-title":"Obstet Gynecol Int"},{"issue":"6","key":"5275_CR8","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.1002\/cncr.24149","volume":"115","author":"A Bois Du","year":"2009","unstructured":"Du Bois A, Reuss A, Pujade-Lauraine E, et al. Role of surgical outcome as prognostic factor in advanced epithelial ovarian Cancer. Cancer. 2009;115(6):1234\u201344.","journal-title":"Cancer"},{"issue":"9990","key":"5275_CR9","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/S0140-6736(14)62223-6","volume":"386","author":"S Kehoe","year":"2015","unstructured":"Kehoe S, Hook J, Nankivell M, et al. Primary chemotherapy versus primary surgery fornewly diagnosed advanced ovarian cancer (CHORUS). Lancet. 2015;386(9990):249\u201357.","journal-title":"Lancet"},{"issue":"10","key":"5275_CR10","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1056\/NEJMoa0908806","volume":"363","author":"I Vergote","year":"2010","unstructured":"Vergote I, Trope CG, Amant F, et al. Neoadjuvant chemotherapy or primary surgery instage IIIC or IV ovarian cancer. N Engl J Med. 2010;363(10):943\u201353.","journal-title":"N Engl J Med"},{"issue":"9","key":"5275_CR11","first-page":"1022","volume":"24","author":"TK Madhuri","year":"2014","unstructured":"Madhuri TK, Haagsma BEN, Williams P, et al. Pathologic analysis of tissue destruction with neutral argon plasma. Int J Gynaecol Cancer. 2014;24(9):1022\u20133.","journal-title":"Int J Gynaecol Cancer"},{"issue":"8","key":"5275_CR12","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.1097\/IGC.0000000000000788","volume":"26","author":"E Panuccio","year":"2016","unstructured":"Panuccio E, Leunen K, van Nieuwenhuysen E, et al. Use of PlasmaJet for peritoneal Carcinomatosis in ovarian Cancer. Int J Gynecol Cancer. 2016;26(8):1521\u20134.","journal-title":"Int J Gynecol Cancer"},{"issue":"3","key":"5275_CR13","first-page":"622","volume":"135","author":"S Butler-Manuel","year":"2014","unstructured":"Butler-Manuel S, Lippiatt J, Madhuri TK. Interval cytoreductive surgery surgery following neo-adjuvant chemotherapy for ovarian cancer using neutral argon plasma (PlasmaJet). GynecolOncol. 2014;135(3):622\u20133.","journal-title":"GynecolOncol"},{"issue":"9","key":"5275_CR14","first-page":"245","volume":"24","author":"TK Madhuri","year":"2014","unstructured":"Madhuri TK, Ashbourne W, Butler-Manuel SA, et al. RCT to evaluate utility and efficacy of neutral argon plasma as NewTechnology in achieving complete Cytoreduction of advanced epithelial ovarian carcinoma-initial feasibility study. Int J Gynaecol Cancer. 2014;24(9):245.","journal-title":"Int J Gynaecol Cancer."},{"key":"5275_CR15","unstructured":"Madhuri T. TA, Ellis P., Ashbourne W. et al. To evaluate PlasmaJet in achieving complete cytoreduction of advanced EOC-interim results from an initial feasibility study. Int J Gynaecol Cancer. 2015 25:9 SUPPL. 1 (1427\u20138)."},{"issue":"1","key":"5275_CR16","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.ygyno.2016.10.030","volume":"144","author":"G Cordeiro Vidal","year":"2017","unstructured":"Cordeiro Vidal G, Babin G. Querleu et al. primary debulking surgery with a plasma device surgery system, for advanced ovarian cancer. Gynecol Oncol. 2017;144(1):223\u20134.","journal-title":"Gynecol Oncol"},{"issue":"10","key":"5275_CR17","doi-asserted-by":"publisher","first-page":"1442","DOI":"10.1007\/s11695-009-0067-5","volume":"20","author":"A Iannelli","year":"2010","unstructured":"Iannelli A, Schneck AS, Gugenheim J. Use of the PlasmaJet System in patients undergoing abdominal lipectomy following massive weight loss. Obes Surg. 2010;20(10):1442\u20137.","journal-title":"Obes Surg"},{"issue":"1","key":"5275_CR18","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/S1701-2163(15)31048-3","volume":"35","author":"MC Renaud","year":"2013","unstructured":"Renaud MC, Sebastianelli A. Optimal cytoreduction with neutral argon plasma energy in selected patients with ovarian and primitive peritoneal cancer. J Obstet Gynaecol Can. 2013;35(1):49\u201352.","journal-title":"J Obstet Gynaecol Can"},{"issue":"2","key":"5275_CR19","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1016\/j.ygyno.2015.11.028","volume":"140","author":"J Seror","year":"2016","unstructured":"Seror J, Bats AS, Habchi H, et al. Optimal surgical cytoreduction of the upper abdomen and the diaphragm for advanced ovarian cancer using PlasmaJet energy. Gynecol Oncol. 2016;140(2):372\u20133.","journal-title":"Gynecol Oncol"},{"issue":"3","key":"5275_CR20","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1016\/j.ygyno.2014.09.007","volume":"135","author":"S Butler-Manuel","year":"2014","unstructured":"Butler-Manuel S, Lippiatt J, Madhuri TK. Interval debulking surgery following neo-adjuvant chemotherapy for ovarian cancer using neutral argon plasma (PlasmaJet (TM)). Gynecol Oncol. 2014;135(3):622.","journal-title":"Gynecol Oncol"},{"key":"5275_CR21","unstructured":"NVOG Kennis agenda 2017\u20132020 p 33. https:\/\/www.nvog.nl\/wp-content\/uploads\/2017\/12\/NVOG-kennisagenda-2017-2020.pdf ."},{"issue":"5","key":"5275_CR22","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1200\/JCO.2002.20.5.1248","volume":"20","author":"RE Bristow","year":"2002","unstructured":"Bristow RE, Tomacruz RS, Armstong DK, et al. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum erea meta-analysis. J Clin Oncol. 2002;20(5):1248\u201359.","journal-title":"J Clin Oncol"},{"key":"5275_CR23","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/1471-2407-12-31","volume":"12","author":"MJ Rutten","year":"2012","unstructured":"Rutten MJ, Gaarenstroom KN, Van Gorp T, et al. Laparoscopy to predict the result of primary cytoreductive surgery in advanced ovarian cancer patients (LapOvCa-trial). BMC Cancer. 2012;12:31.","journal-title":"BMC Cancer"},{"key":"5275_CR24","doi-asserted-by":"crossref","unstructured":"Forstner R, Sala E, Kinkel K, Spencer JA, European Society of Urogenital R. ESUR guidelines: ovarian cancer staging and follow-up. Eur Radiol. 2010;20(12):2773\u201380.","DOI":"10.1007\/s00330-010-1886-4"},{"issue":"6","key":"5275_CR25","doi-asserted-by":"publisher","first-page":"1775","DOI":"10.1148\/rg.326125511","volume":"32","author":"S Nougaret","year":"2012","unstructured":"Nougaret S, Addley HC, Colombo PE, Fujii S, Al Sharif SS, Tirumani SH, et al. Ovarian carcinomatosis: how the radiologist can help plan the surgical approach. Radiographics. 2012;32(6):1775\u2013800 discussion 800-3.","journal-title":"Radiographics"},{"issue":"3","key":"5275_CR26","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1016\/j.ygyno.2014.07.002","volume":"134","author":"RS Suidan","year":"2014","unstructured":"Suidan RS, Ramirez PT, Sarasohn DM, et al. A multicenter prospective trial evaluating theability of preoperative computed tomography scan and serum CA-125 to predict suboptimal cytoreduction at primary debulking surgery for advanced ovarian, fallopian tube, and peritoneal cancer. Gynecol Oncol. 2014;134(3):455\u201361.","journal-title":"Gynecol Oncol"},{"issue":"6","key":"5275_CR27","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1111\/1471-0528.12992","volume":"122","author":"J Borley","year":"2015","unstructured":"Borley J, Wilhelm-Benartzi C, Yazbek J, et al. Radiological predictors of cytoreductive outcomes in patients with advanced ovarian cancer. BJOG. 2015;122(6):843\u20139.","journal-title":"BJOG"},{"issue":"3","key":"5275_CR28","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1097\/IGC.0000000000000368","volume":"25","author":"MJ Rutten","year":"2015","unstructured":"Rutten MJ, van de Vrie R, Bruining A, et al. Predicting surgical outcome in patients with International Federation of Gynecology and Obstetrics Stage III or IV ovarian Cancer using computed tomography: a systematic review of prediction models. Int J Gynaecol Cancer. 2015;25(3):407\u201315.","journal-title":"Int J Gynaecol Cancer."},{"issue":"6","key":"5275_CR29","doi-asserted-by":"publisher","first-page":"1438","DOI":"10.1016\/j.fertnstert.2016.07.1097","volume":"106","author":"H Roman","year":"2016","unstructured":"Roman H, Moatassim-Drissa S, Marty N, Milles M, Vallee A, Desnyder E, et al. Rectal shaving for deep endometriosis infiltrating the rectum: a 5-year continuous retrospective series. Fertil Steril. 2016;106(6):1438\u201345 e2.","journal-title":"Fertil Steril"},{"issue":"8","key":"5275_CR30","first-page":"1326","volume":"20","author":"Y Sonoda","year":"2010","unstructured":"Sonoda Y, Olvera N, Chi DS, Brown CL, Abu-Rustum NR, Levine DA. Pathologic analysis of ex vivo plasma energy tumour destruction in patients with ovarian or peritoneal cancer. Int J Gynecol Cancer. 2010;20(8):1326\u201330.","journal-title":"Int J Gynecol Cancer"},{"issue":"2","key":"5275_CR31","first-page":"46","volume":"11","author":"TK Madhuri","year":"2016","unstructured":"Madhuri TK, Butler-Manuel SA. Neutral argon plasma in Gynaecologic oncology surgery. Gyn Cancer. 2016 May-June;11(2):46\u20137.","journal-title":"Gyn Cancer"},{"key":"5275_CR32","unstructured":"N. Bourdel HR, A.S. Azuar, E. Wassim, P. Dechelotte, R. Botchorishvili, G. Mage, M. canis. Comparison between resection, bipolar coagulation and PlasmaJet: a preliminary animal study. Gynaecological Surgery 2010;7 SUPPL. 1 (S159)."},{"key":"5275_CR33","unstructured":"Richtlijn voor het uitvoeren van economische evaluaties in de gezondheidszorg en Kostenhandleiding: Methodologie van kosten onderzoek en referentieprijzen voor economische evaluaties in de gezondheidszorg. https:\/\/www.zorginstituutnederland.nl\/publicaties\/publicatie\/2016\/02\/29\/richtlijn-voor-het-uitvoeren-van-economische-evaluaties-in-de-gezondheidszorg ."},{"key":"5275_CR34","unstructured":"Institute of Health Policy & Management. Questionnaires for the measurement of costs in economic evaluations. https:\/\/www.imta.nl\/questionnaires\/ ."},{"key":"5275_CR35","doi-asserted-by":"crossref","DOI":"10.1093\/oso\/9780195108248.001.0001","volume-title":"Cost-Effectiveness in Health and Medicine","author":"M Gold","year":"1996","unstructured":"Gold M, Siegel J, Russell L, Weinstein M. Cost-Effectiveness in Health and Medicine. New York: Oxford University Press; 1996."},{"issue":"5","key":"5275_CR36","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1111\/j.1524-4733.2007.00187.x","volume":"10","author":"JA Mauskopf","year":"2007","unstructured":"Mauskopf JA, Sullivan SD, Annemans L, et al. Principles of good practice for budget impact analysis: report of the ISPORTask force on good research practices--budget impact analysis. Value Health. 2007 Sep-Oct;10(5):336\u201347.","journal-title":"Value Health"},{"key":"5275_CR37","doi-asserted-by":"crossref","unstructured":"Sier MF, et al. Home visits as part of a new care pathway (iAID) to improve quality of care and quality of life in colostomy patients. Colorectal Dis. 2017; Feb 13 Epub.","DOI":"10.1111\/codi.13630"},{"key":"5275_CR38","doi-asserted-by":"crossref","unstructured":"van Driel WJ, Sikorska K, Schagen-van Leeuwen J, et al. A phase 3 trial of hyperthermic intraperitoneal chemotherapy (HIPEC) for ovarian cancer. J Clin Oncol. 2017;35 abstr 5519.","DOI":"10.1200\/JCO.2017.35.15_suppl.5519"},{"issue":"1","key":"5275_CR39","first-page":"41","volume":"8","author":"WJ Driel van","year":"2011","unstructured":"van Driel WJ. De OVHIPEC-studie. NTvO. 2011;8(1):41\u20133.","journal-title":"NTvO"},{"key":"5275_CR40","doi-asserted-by":"publisher","unstructured":"van Driel WJ, Lok CA, Verwaal V, Sonke GS. The role of hyperthermic intraperitoneal chemotherapy in ovarian cancer. 2015;16(4):14. https:\/\/doi.org\/10.1007\/s11864-015-0329-5 .","DOI":"10.1007\/s11864-015-0329-5"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-019-5275-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12885-019-5275-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-019-5275-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,14]],"date-time":"2024-07-14T01:39:29Z","timestamp":1720921169000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-019-5275-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1,14]]},"references-count":40,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["5275"],"URL":"https:\/\/doi.org\/10.1186\/s12885-019-5275-3","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,1,14]]},"assertion":[{"value":"13 October 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 January 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 January 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study will be carried out according to the standards outlined in the Declaration of Helsinki. Ethics committee approval has been granted. All procedures involving patients have been approved by the Medical Ethical Committee of Erasmus Medical Centre Rotterdam in the Netherlands (trial protocol version 3.0 d.d. 20th November 2017, NL62035.078.17).Patients from the following Dutch hospitals may be included: Albert Schweitzer (Dordrecht), Bravis (Bergen op Zoom), Catharina Cancer Institute (Eindhoven), Erasmus MC (Rotterdam), Franciscus Gasthuis and Vlietland (Rotterdam), Groene Hart Hospital (Gouda), Haags Medisch Centrum (Den Haag), Haga Hospital (Den Haag), Leids University MC (Leiden), Medisch Spectrum Twente (Enschede), Reinier de Graaf Groep (Delft).Patients will receive verbal and written information from their gynaecologist during the intake for surgery. Informed consent will be obtained from all participants to use the data for analyses. Randomization happens after signing of the Informed Consent.All data will be anonymously processed. Participants will be able to resign at any time without statement of reasons.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"58"}}